logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Cost-effectiveness of Clozapine in patients with high and low levels of hospital use.

    Article - En anglais

    Background 

    This study examined the relationship between pretreatment hospital use and the cost-effectiveness of clozapine in the treatment of refractory schizophrenia.

    Methods 

    Data from a 15-site randomized clinical trial were used to compare clozapine with haloperidol in hospitalized Veterans Affairs patients with refractory schizophrenia (n=423).

    Outcomes were compared among those with many days in the hospital use (hereafter, high hospital users) (n=141 ; mean=215 psychiatric hospital days in the year prior to study entry) and those with few days in the hospital use (hereafter, low hospital users) (n=282 ; mean=58 hospital days).

    Analyses were conducted with the full intention-to-treat sample (n=423) and with crossovers excluded (n=291).

    Results 

    Clozapine treatment resulted in greater reduction in hospital use among high hospital users (35 days less than controls, P=02) than among low users (21 days less than controls, P=05).

    Patients taking clozapine also had lower health care costs ; after including the costs of both medications and other health services, costs were $7134 less than for controls among high hospital users (P=14) but only $759 less than for controls among low hospital users (P=82).

    Clinical improvement in the domains of symptoms, quality of life, extrapyramidal symptoms, and a synthetic measure of multiple outcomes favored clozapine in both high and low hospital user groups. (...)

    Mots-clés Pascal : Schizophrénie, Chimiothérapie, Efficacité traitement, Clozapine, Neuroleptique, Atypique, Psychotrope, Analyse coût efficacité, Hospitalisation, Economie santé, Homme, Psychose, Dibenzodiazépine

    Mots-clés Pascal anglais : Schizophrenia, Chemotherapy, Treatment efficiency, Clozapine, Neuroleptic, Atypical, Psychotropic, Cost efficiency analysis, Hospitalization, Health economy, Human, Psychosis

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0339330

    Code Inist : 002B02B03. Création : 14/12/1999.